title: SGLT2 inhibitors: their potential reduction in blood pressure.
abstract: The sodium glucose co-transporter 2 (SGLT2) inhibitors represent a promising treatment option for diabetes and its common comorbidity, hypertension. Emerging data suggests that the SGLT2 inhibitors provide a meaningful reduction in blood pressure, although the precise mechanism of the blood pressure drop remains incompletely elucidated. Based on current data, the blood pressure reduction is partially due to a combination of diuresis, nephron remodeling, reduction in arterial stiffness, and weight loss. While current trials are underway focusing on cardiovascular endpoints, the SGLT2 inhibitors present a novel treatment modality for diabetes and its associated hypertension as well as an opportunity to elucidate the pathophysiology of hypertension in diabetes.
authors.affiliation: Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: George
authors.initials: G
authors.lastname: Maliha
authors.affiliation: Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: townsend@exchange.upenn.edu.
authors.forename: Raymond R
authors.initials: RR
authors.lastname: Townsend
mesh_terms: D001794:Blood Pressure / Q000187:drug effects* / Q000502:physiology; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000503:physiopathology; D004231:Diuresis / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology*; D007668:Kidney / Q000503:physiopathology; D009318:Natriuresis / Q000187:drug effects / Q000502:physiology; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D059289:Vascular Stiffness / Q000187:drug effects / Q000502:physiology
chemical_list: C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors
keywords: Canagliflozin; dapagliflozin; empagliflozin; hypertension